Bone marrow mesenchymal stem cell-derived endothelial cells increase capillary density and accelerate angiogenesis in mouse hindlimb ischemia model

Yao, Ziping; Liu, Huihui; Yang, Min; Bai, Yun; Zhang, Bihui; Wang, Chengen; Zhang, Yan; Niu, Guochen; Zou, Yinghua; Li, Yuan

doi:10.1186/s13287-020-01710-x

Cited by 32 publications

(26 citation statements)

References 18 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Various studies have demonstrated the role of MSCs in angiogenesis and arteriogenesis, useful in improving coronary heart disease, skin wound healing, and hindlimb ischemia [ 56 – 58 ]. Acting as intermediary of angiogenesis, MSCs release various growth factors, such as vascular endothelial growth factor (VEGF), fibroblast growth factors (FGFs), hepatocyte growth factor (HGF), stromal cell-derived factor 1 (SDF-1), and angiopoietin-1 (ANG-1).…”

Section: Secretome Angiogenic Pro-survival and Tissue Regeneration Propertiesmentioning

confidence: 99%

Clinical Trials Based on Mesenchymal Stromal Cells are Exponentially Increasing: Where are We in Recent Years?

Galderisi

Peluso²,

Bernardo

2021

Stem Cell Rev and Rep

130

View full text Add to dashboard Cite

Mesenchymal stromal cells (MSCs), present in the stromal component of several tissues, include multipotent stem cells, progenitors, and differentiated cells. MSCs have quickly attracted considerable attention in the clinical field for their regenerative properties and their ability to promote tissue homeostasis following injury. In recent years, MSCs mainly isolated from bone marrow, adipose tissue, and umbilical cord—have been utilized in hundreds of clinical trials for the treatment of various diseases. However, in addition to some successes, MSC-based therapies have experienced several failures. The number of new trials with MSCs is exponentially growing; still, complete results are only available for a limited number of trials. This dearth does not help prevent potentially inefficacious and unnecessary clinical trials. Results from unsuccessful studies may be useful in planning new therapeutic approaches to improve clinical outcomes. In order to bolster critical analysis of trial results, we reviewed the state of art of MSC clinical trials that have been published in the last six years. Most of the 416 published trials evaluated MSCs’ effectiveness in treating cardiovascular diseases, GvHD, and brain and neurological disorders, although some trials sought to treat immune system diseases and wounds and to restore tissue. We also report some unorthodox clinical trials that include unusual studies. Graphical abstract

show abstract

Section: Secretome Angiogenic Pro-survival and Tissue Regeneration Propertiesmentioning

confidence: 99%

Clinical Trials Based on Mesenchymal Stromal Cells are Exponentially Increasing: Where are We in Recent Years?

Galderisi

Peluso²,

Bernardo

2021

Stem Cell Rev and Rep

130

View full text Add to dashboard Cite

show abstract

“…The endothelial-like cells (ECs) were injected into the paracentral thigh of the gastrocnemius muscle in 3 various places within 1 day after the model surgery. The ECs could increase therapeutic result of angiogenesis and have stronger ability in vascular creation [78].…”

Section: Bone Marrow Mesenchymal Stem Cellsmentioning

confidence: 99%

Human stem cells – sources, sourcing and in vitro methods

Szubarga

Kamińska

Kotlarz

et al. 2021

Medical Journal of Cell Biology

View full text Add to dashboard Cite

Stem cells are an important subject of research, and are increasingly used in the treatment of various diseases. Due to the development of advanced in vitro techniques, they have become an integral part of modern medicine. The sources of human stem cells are primarily bone marrow and adipose tissue, although non – embryonic stem cells are also scattered throughout the body. Notably, recent research has focused on stem cells found in the oral cavity, both in the dental pulp and oral mucosa. Furthermore, isolation of stem cells from umbilical cord blood is also becoming increasingly popular, while wharton’s jelly and amniotic fluid also seem to be an interesting source of stem cells. The safety and efficacy of stem cells use can be established by animal studies, which are a key element of preclinical research. Mouse, rat and pig models allow for testing of stem cell therapies. Recent studies primarily use mesenchymal stem cells such as mouse – adipose derived mesenchymal stem cells and mouse and rat hematopoietic stem cells. Great hope for future therapies is the use of bioengineering to program cells into induced stem cells, which have the biggest ability for differentiation and transdifferentiation, which carries no risk of teratogenesis. Stem cells are used in many areas of medicine, especially in regenerative medicine, with a growing interest in orthopedics and in the treatment of heart failure. Mesenchymal stem cells are the most used stem cell type, which despite their limited ability to differentiate, give great therapeutic results, mainly due to their immunomodulating effect. Recent studies have even shown that the use of mesenchymal stem cells may be useful in the treatment of COVID-19. Moreover, Research on the use of mesenchymal stem cells in the treatment of Crohn’s disease, acute-graft-versus-host disease and type I diabetes are also promising. The aim of the current review is to present and systematize current knowledge about stem cells, their use and related in vitro research. Running title: Research and use of human stem cells

show abstract

“…Otherwise, MSCs have been found to promote cardiomyocyte DNA synthesis and proliferation, and signal cardiomyocyte gene upregulation (including VEGF, cyclin A2, and TGF-β2) ( 194 , 233 ). Through their paracrine activity, they also prevent cardiomyocyte cell apoptosis ( 188 , 221 , 234 – 236 ) with several studies observing a reduced activation of the caspase-3 pathway in cardiomyocytes exposed to either MSC-derived exosomes ( 236 ) or conditioned media ( 237 ).…”

Section: Msc Transplantation Could Attenuate Damage and Facilitate Rementioning

confidence: 99%

The Role of MSC Therapy in Attenuating the Damaging Effects of the Cytokine Storm Induced by COVID-19 on the Heart and Cardiovascular System

Ellison

Colley

O’Brien

et al. 2020

Front. Cardiovasc. Med.

View full text Add to dashboard Cite

The global pandemic of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) that causes coronavirus disease 2019 (COVID-19) has led to 47 m infected cases and 1. 2 m (2.6%) deaths. A hallmark of more severe cases of SARS-CoV-2 in patients with acute respiratory distress syndrome (ARDS) appears to be a virally-induced over-activation or unregulated response of the immune system, termed a “cytokine storm,” featuring elevated levels of pro-inflammatory cytokines such as IL-2, IL-6, IL-7, IL-22, CXCL10, and TNFα. Whilst the lungs are the primary site of infection for SARS-CoV-2, in more severe cases its effects can be detected in multiple organ systems. Indeed, many COVID-19 positive patients develop cardiovascular complications, such as myocardial injury, myocarditis, cardiac arrhythmia, and thromboembolism, which are associated with higher mortality. Drug and cell therapies targeting immunosuppression have been suggested to help combat the cytokine storm. In particular, mesenchymal stromal cells (MSCs), owing to their powerful immunomodulatory ability, have shown promise in early clinical studies to avoid, prevent or attenuate the cytokine storm. In this review, we will discuss the mechanistic underpinnings of the cytokine storm on the cardiovascular system, and how MSCs potentially attenuate the damage caused by the cytokine storm induced by COVID-19. We will also address how MSC transplantation could alleviate the long-term complications seen in some COVID-19 patients, such as improving tissue repair and regeneration.

show abstract

Bone marrow mesenchymal stem cell-derived endothelial cells increase capillary density and accelerate angiogenesis in mouse hindlimb ischemia model

Cited by 32 publications

References 18 publications

Clinical Trials Based on Mesenchymal Stromal Cells are Exponentially Increasing: Where are We in Recent Years?

Clinical Trials Based on Mesenchymal Stromal Cells are Exponentially Increasing: Where are We in Recent Years?

Human stem cells – sources, sourcing and in vitro methods

The Role of MSC Therapy in Attenuating the Damaging Effects of the Cytokine Storm Induced by COVID-19 on the Heart and Cardiovascular System

Contact Info

Product

Resources

About